Literature DB >> 21208912

In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.

Silva Hilburn1, Aileen Rowan, Maria-Antonietta Demontis, Aidan MacNamara, Becca Asquith, Charles R M Bangham, Graham P Taylor.   

Abstract

BACKGROUND: The roles of the human T-lymphotropic virus type 1 (HTLV-1) basic leucine zipper (HBZ) gene are not clearly understood. We examined CD8+ and CD4+ T cell responses to HBZ and compared these with Tax responses.
METHOD: Interferon (IFN)-γ and interleukin (IL)-2-secreting T cells were detected by enzyme-linked immunosorbent spot (ELISpot) assays of freshly isolated peripheral blood mononuclear cells (PBMCs) stimulated with synthetic HBZ or Tax peptides. Ten patients with HTLV-1-associated myelopathy (HAM) and 20 asymptomatic HTLV-1 carriers (ACs), (10 high, 10 low viral load).
RESULTS: Of 30 study participants, 17 had detectable HBZ-specific CD4+ T cells and 12 had HBZ-specific CD8+ T cell responses. Detection of Tax-specific CD4+ T cells (IL-2- or IFN-γ-secreting) did not differ by disease status, but Tax-specific CD8+ T cell responses were more commonly detected in patients with HAM. HBZ-specific CD4+ or CD8+ T cells were less likely to be detected than Tax-specific T cells. IL-2-secreting Tax-specific CD8+ T cells, and IFN-γ-secreting Tax-specific CD4+ T cells were associated with HAM. Low viral load, asymptomatic HTLV-1 carriage was associated with IL-2-secreting CD8+ T cells specific for HBZ.
CONCLUSION: HBZ protein is expressed in vivo in patients with HAM and in ACs. Our results are consistent with the idea that the T cell response to HBZ plays an important part in restricting HTLV-1 viral load.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208912      PMCID: PMC3071236          DOI: 10.1093/infdis/jiq078

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan.

Authors:  K Arisawa; M Soda; S Endo; K Kurokawa; S Katamine; I Shimokawa; T Koba; T Takahashi; H Saito; H Doi; S Shirahama
Journal:  Int J Cancer       Date:  2000-02-01       Impact factor: 7.396

2.  Uveitis associated with human T-cell lymphotropic virus type I.

Authors:  M Mochizuki; T Watanabe; K Yamaguchi; K Yoshimura; S Nakashima; M Shirao; S Araki; K Takatsuki; S Mori; N Miyata
Journal:  Am J Ophthalmol       Date:  1992-08-15       Impact factor: 5.258

3.  Human T-cell leukemia virus type 1 HBZ protein bypasses the targeting function of ubiquitination.

Authors:  Osamu Isono; Takayuki Ohshima; Yasushi Saeki; Jun Matsumoto; Makoto Hijikata; Keiji Tanaka; Kunitada Shimotohno
Journal:  J Biol Chem       Date:  2008-09-19       Impact factor: 5.157

4.  HTLV-1 HBZ suppresses AP-1 activity by impairing both the DNA-binding ability and the stability of c-Jun protein.

Authors:  Jun Matsumoto; Takayuki Ohshima; Osamu Isono; Kunitada Shimotohno
Journal:  Oncogene       Date:  2005-02-03       Impact factor: 9.867

5.  HTLV-1 and polymyositis in Jamaica.

Authors:  O S Morgan; P Rodgers-Johnson; C Mora; G Char
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

6.  Construction and characterization of a human T-cell lymphotropic virus type 3 infectious molecular clone.

Authors:  Sébastien Alain Chevalier; Nga Ling Ko; Sara Calattini; Adeline Mallet; Marie-Christine Prévost; Kylene Kehn; John N Brady; Fatah Kashanchi; Antoine Gessain; Renaud Mahieux
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

7.  A novel alternative splicing isoform of human T-cell leukemia virus type 1 bZIP factor (HBZ-SI) targets distinct subnuclear localization.

Authors:  Ken Murata; Toshihisa Hayashibara; Kazuyuki Sugahara; Akiko Uemura; Taku Yamaguchi; Hitomi Harasawa; Hiroo Hasegawa; Kazuto Tsuruda; Toshiro Okazaki; Takehiko Koji; Takayuki Miyanishi; Yasuaki Yamada; Shimeru Kamihira
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

8.  In vivo expression of the HBZ gene of HTLV-1 correlates with proviral load, inflammatory markers and disease severity in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Mineki Saito; Toshio Matsuzaki; Yorifumi Satou; Jun-Ichirou Yasunaga; Kousuke Saito; Kimiyoshi Arimura; Masao Matsuoka; Yoshiro Ohara
Journal:  Retrovirology       Date:  2009-02-19       Impact factor: 4.602

9.  Ancient, independent evolution and distinct molecular features of the novel human T-lymphotropic virus type 4.

Authors:  William M Switzer; Marco Salemi; Shoukat H Qari; Hongwei Jia; Rebecca R Gray; Aris Katzourakis; Susan J Marriott; Kendle N Pryor; Nathan D Wolfe; Donald S Burke; Thomas M Folks; Walid Heneine
Journal:  Retrovirology       Date:  2009-02-02       Impact factor: 4.602

10.  Characteristic expression of HTLV-1 basic zipper factor (HBZ) transcripts in HTLV-1 provirus-positive cells.

Authors:  Tetsuya Usui; Katsunori Yanagihara; Kunihiro Tsukasaki; Ken Murata; Hiroo Hasegawa; Yasuaki Yamada; Shimeru Kamihira
Journal:  Retrovirology       Date:  2008-04-22       Impact factor: 4.602

View more
  39 in total

1.  Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs.

Authors:  Francesca Rende; Ilaria Cavallari; Alberto Corradin; Micol Silic-Benussi; Frederic Toulza; Gianna M Toffolo; Yuetsu Tanaka; Steven Jacobson; Graham P Taylor; Donna M D'Agostino; Charles R M Bangham; Vincenzo Ciminale
Journal:  Blood       Date:  2011-03-11       Impact factor: 22.113

Review 2.  Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.

Authors:  Michael D Lairmore; Rajaneesh Anupam; Nadine Bowden; Robyn Haines; Rashade A H Haynes; Lee Ratner; Patrick L Green
Journal:  Viruses       Date:  2011-07-12       Impact factor: 5.048

Review 3.  Human T-cell lymphotropic virus: a model of NF-κB-associated tumorigenesis.

Authors:  Zhaoxia Qu; Gutian Xiao
Journal:  Viruses       Date:  2011-06       Impact factor: 5.048

4.  The HIV-1 antisense protein (ASP) induces CD8 T cell responses during chronic infection.

Authors:  Anne Bet; Emmanuel Atangana Maze; Anju Bansal; Sarah Sterrett; Antoine Gross; Stéphanie Graff-Dubois; Assia Samri; Amélie Guihot; Christine Katlama; Ioannis Theodorou; Jean-Michel Mesnard; Arnaud Moris; Paul A Goepfert; Sylvain Cardinaud
Journal:  Retrovirology       Date:  2015-02-10       Impact factor: 4.602

5.  The roles of acquired and innate immunity in human T-cell leukemia virus type 1-mediated diseases.

Authors:  Mari Kannagi; Atsuhiko Hasegawa; Ayako Takamori; Shuichi Kinpara; Atae Utsunomiya
Journal:  Front Microbiol       Date:  2012-09-03       Impact factor: 5.640

6.  Expansion in CD39⁺ CD4⁺ immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications.

Authors:  Fabio E Leal; Lishomwa C Ndhlovu; Aaron M Hasenkrug; Fernanda R Bruno; Karina I Carvalho; Harry Wynn-Williams; Walter K Neto; Sabri S Sanabani; Aluisio C Segurado; Douglas F Nixon; Esper G Kallas
Journal:  PLoS Negl Trop Dis       Date:  2013-02-07

7.  Is There a Role for HTLV-1-Specific CTL in Adult T-Cell Leukemia/Lymphoma?

Authors:  Aileen G Rowan; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2011-11-30

8.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06

Review 9.  Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito
Journal:  J Neurovirol       Date:  2013-08-14       Impact factor: 3.739

10.  Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection.

Authors:  Anat Melamed; Daniel J Laydon; Nicolas A Gillet; Yuetsu Tanaka; Graham P Taylor; Charles R M Bangham
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.